Danone Posts Strong Q2 Growth on Health-Focused Portfolio
Event summary
- Danone reported Q2 sales up +4.2% LFL, with H1 sales reaching €13.9bn (+3.5% LFL).
- Recurring operating margin improved by +12 bps to 13.3%, driven by productivity gains.
- Free cash flow stood at €0.9bn, with net debt slightly increasing to €9.0bn.
- Danone confirmed 2026 guidance: LFL sales growth between +3% and +5%.
- Recent acquisitions include Huel and Made Group in APAC.
The big picture
Danone's strong Q2 performance underscores the resilience of its health-focused portfolio, particularly in Specialized Nutrition and Waters. The company's strategic acquisitions in APAC signal a push into high-growth markets, while operational efficiency gains offset inflationary pressures. As consumer demand for functional and medical nutrition products grows, Danone's multi-engine growth model positions it favorably against competitors.
What we're watching
- Execution Risk
- Whether Danone can sustain its momentum amid inflationary pressures and geopolitical instability.
- Market Expansion
- The pace at which recent acquisitions in APAC will integrate and contribute to growth.
- Operational Efficiency
- How Danone balances reinvestments behind key drivers with margin expansion goals.